Cover Image

Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial

This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemothera...

Full description

Saved in:
Bibliographic Details
Main Authors: Glasmacher, Axel (Author) , Goldschmidt, Hartmut (Author) , Mezger, Jörg (Author) , Haferlach, Torsten (Author) , Schmidt-Wolf, Ingo G. H. (Author) , Gieseler, Frank (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2004
In: Haematologica
Year: 2004, Volume: 89, Issue: 3, Pages: 371-373
ISSN:1592-8721
DOI:10.3324/%x
Online Access:Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/3017
Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/%25x
Get full text
Author Notes:Axel Glasmacher, Hartmut Goldschmidt, Jörg Mezger, Torsten Haferlach, Ingo G.H. Schmidt-Wolf, Frank Gieseler
Description
Summary:This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.
Item Description:DOI fehlerhaft
Gesehen am 25.02.2022
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/%x

Similar Items